中药三黄固本止咳方治疗稳定期慢性阻塞性肺疾病的效果:一项随机双盲安慰剂对照试验的研究方案
本研究为随机双盲安慰剂对照试验,计划纳入100例肺脾气虚证稳定期慢性阻塞性肺疾病患者,按1:1随机分为三黄固本止咳方组(N=50)与安慰剂组(N=50),两组均按2017年GOLD指南接受基础治疗,干预24周并随访28周,评估急性加重频率与持续时间、肺功能、中医症状积分、运动能力和生活质量。
要点
- 三黄固本止咳方在临床前研究中显示出对慢性阻塞性肺疾病的良好临床疗效。
- 动物实验显示其具有黏膜免疫屏障功能,可维持气道壁完整性、减少炎症细胞浸润。
- 研究假设该方可减少急性加重频率和持续时间、改善稳定期患者运动能力。
核心结论
- 研究假设三黄固本止咳方将有助于减少肺脾气虚证稳定期慢性阻塞性肺疾病患者的急性加重频率和持续时间,并改善运动能力。
- 该研究可能为慢性阻塞性肺疾病患者建立一种不同于临床同类适应症现有药物的新治疗方法。
研究设计与样本
- 研究为随机、双盲、安慰剂对照试验,计划招募100例肺脾气虚证稳定期慢性阻塞性肺疾病患者。
- 患者随机分为三黄固本止咳方治疗组(N=50)与安慰剂治疗组(N=50)。
- 两组均按2017年GOLD慢性阻塞性肺疾病指南接受基础治疗,并尽量坚持原有治疗,研究期间出现急性加重时给予现有一般治疗。
- 两组均接受24周干预,治疗结束后再随访28周,于治疗24周及治疗后28周评估患者状态。
主要发现
- 临床前研究显示三黄固本止咳方在慢性阻塞性肺疾病中具有良好的临床疗效。
- 动物实验显示该方具有黏膜免疫屏障功能,可维持气道壁完整性、减少炎症细胞浸润、促进炎症损伤修复并缓解气道狭窄状况。
关键数值与推荐
- 主要结局指标包括急性加重的频率和持续时间、肺功能、中医症状积分、运动能力和生活质量。
- 试验注册号为ChiCTR1800016349,于2018年5月26日注册。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to the large number of patients, high mortality rate as well as high social costs and economic burden, chronic obstructive pulmonary disease (COPD) has become one of the most important health problems around the world, which has attracted people's attention. Currently, Chinese herbs have been widely used as alternative medicine (CAM) for COPD patients. The Chinese herbal formula San-Huang Gu-Ben Zhi-Ke (SHGBZK) has shown good clinical efficacy in COPD in preclinical studies. Animal experiments have shown that it has mucosal immune barrier function and can maintain airway wall integrity, reduce inflammatory cell infiltration, promote inflammatory damage repair, and relieve narrow airway conditions. METHODS/DESIGN: This study is a randomized, double-blind, placebo-controlled trial. A total of 100 patients with stable COPD diagnosed with deficiency of lung qi and spleen qi will be recruited and randomly assigned to one of two treatment groups: SHGBZK treatment, N = 50; placebo treatment, N = 50. The two groups will receive basic treatment for COPD according to the 2017 GOLD Guidelines for Chronic Obstructive Pulmonary Disease. Patients will stick to the treatment they used to take as much as possible, and will be given present general treatment when acute exacerbation of COPD occurs during the study. Both groups will receive a 24-week intervention and patient status will be assessed at 24 weeks and then 28 weeks after treatment. After the 24-week treatment, patients will be followed up for another 28 weeks. Outcome measures, including the frequency and duration of acute exacerbation, lung function, traditional Chinese medicine symptom score, exercise capacity, and quality of life will be assessed. DISCUSSION: It is hypothesized that SHGBZK will have beneficial effects in reducing the frequency and duration of acute exacerbations, improving the exercise capacity function of patients with stable COPD diagnosed with a deficiencies in lung qi and spleen qi. This study may establish a new treatment method for COPD patients, differentiating it from other drugs in clinical use used for similar clinical indications. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR1800016349. Registered on 26 May 2018.
引用
- Zu Y, Li D, Lei X, et al. Effects of the Chinese herbal formula San-Huang Gu-Ben Zhi-Ke treatment on stable chronic obstructive pulmonary disease: study protocol of a randomized, double-blind, placebo-controlled trial. Trials. 2019. PMID: 31775843. doi:10.1186/s13063-019-3729-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。